ClinicalTrials.gg
RecruitingNCT07487376Updated May 29, 2026

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of IBIO-600 in Overweight or Obese Adults

A Phase 1 interventional study of IBIO-600 and Placebo in Overweight , Obesity, sponsored by iBio, Inc.. Recruiting at 1 site in Australia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-29.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by iBio, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 188 studies in Obesity with a site in Australia — 56 open to participants now, 74 under way, 34 of them phase 3. Obesity · Australia.

Planned enrollment
146th of 169
32 · median 180
Started
2026
with 40 others
Phase 1
33 of 188
15 open now
Primary completion
2027-05
later than 19 of 73 live
Registered
160th of 188
by date

Among the 188 studies in Obesity with a site in Australia, this one is the 146th largest by planned enrollment of the 169 interventional ones that give a count, is one of 41 that started in 2026, is one of 33 in phase 1, reaches primary completion later than 19 of the 73 other live ones, and was the 160th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

56 of the 188 studies in Obesity with a site in Australia are open now. Recruiting first, the newest first:

50 more — sign in →

All 56 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 188 studies in Obesity with a site in Australia, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn which dose of study drug IBIO-600 has the right balance of safety, tolerability and impact on body composition in overweight and obese adult participants.

Read the detailed description

The study is a single ascending dose study, with participants monitored for 9 months after administration.

This clinical trial will seek to address the following:

  • Which dose of the study drug is most effective.
  • How safe the study drug is and how well participants tolerate it.
  • How much of the study drug can be found in blood (pharmacokinetics).
  • How the study drug affects the body (pharmacodynamics).
  • How the body's immune system responds to the study drug (immunogenicity).
  • How the body's composition and physical function may change over the course of the study.
03

Conditions studied

  • Overweight , Obesity

Browse trials for

Keywords

  • iBio
  • Overweight
  • Obesity
  • Phase I
  • IBIO-600
  • Myostatin
04

In context

Obesity Reclassified

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

This study's planned enrollment of 32 is below the median of 67 across 9,043 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

iBio, Inc. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 to 65 years of age
  • In good general health, with no significant medical history
  • between ≥ 27.0 and ≤ 34.90 kg/m2
  • History of self-reported stable body weight (defined as change of no more or less than ± 5%) within 90 days of Screening.
  • Willingness to refrain from any reconstructive and/or cosmetic surgery and/or non-invasive cosmetic procedure that may affect body weight during the study
  • Must be fully ambulatory without any chronic orthopedic diseases or reliance on crutches, walkers, or a wheelchair that may preclude normal activity.
  • Be a nonsmoker/nonvaper and must not have used any nicotine or synthetic type products within 1 month prior to randomization.
  • Must not be pregnant or breastfeeding
  • Woman of (WOCBP) or fertile man agrees to use an acceptable method of from the start of Screening until study completion, or for a minimum of 9 months following the last dose of IP, whichever period is longer.

Exclusion criteria

Exclusion Criteria:

  • An underlying physical or psychological medical conditions that, in the opinion of the PI or medical designee, would make the participant unlikely to comply with the protocol or complete the study per protocol.
  • History or active diagnosis of diabetes (Type 1 or 2).
  • History of insulinoma or recurrent hypoglycemia (≥ 3 episodes in past 3 months).
  • History or presence of muscle disease
  • History of or active cardiovascular disease including clinically significant arrhythmias, Class I-IV heart failure, coronary artery disease, thromboembolic event, or pulmonary hypertension.
  • Clinically significant laboratory abnormalities that would preclude participation in the study.
  • History of , except for non-melanoma skin cancer excised > 2 years ago or cervical intraepithelial neoplasia successfully treated > 5 years prior to randomization.
  • History or presence of any condition associated with significant .
  • History of substance abuse or dependency, or recreational IV drug use within the past 5 years (self-reported).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    IBIO-600 (Cohort 1)

    Drug: IBIO-600

  • Experimental
    IBIO-600 (Cohort 2)

    Drug: IBIO-600

  • Experimental
    IBIO-600 (Cohort 3)

    Drug: IBIO-600

  • Experimental
    IBIO-600 (Cohort 4)

    Drug: IBIO-600

  • Placebo comparator
    Placebo

    Matching placebo

    Drug: Placebo

Interventions

  • DrugIBIO-600

    IBIO-600 Subcutaneous injection

  • DrugPlacebo

    Matching placebo; subcutaneous injection

07

What researchers measure

Primary outcomes

  1. Assessment of the safety and tolerability of a single dose of IBIO-600

    Incidence, severity, and relationship to study treatment of TEAEs and SAEs, as determined by clinical laboratory evaluations, vital signs, physical examinations, and ECGs.

    Time frame: From Day 1 through Day 252 (end of study).

Secondary outcomes

  1. Pharmacokinetics of a single dose of IBIO-600

    Maximum observed serum concentration (Cmax)

    Time frame: Baseline up to Week 36

  2. Pharmacokinetics of a single dose of IBIO-600

    Time to maximum concentration (Tmax)

    Time frame: Baseline up to Week 36

  3. Pharmacokinetics of a single dose of IBIO-600

    Area under the curve (AUC)

    Time frame: Baseline to the last measurable concentration (AUC0-last)

  4. Pharmacokinetics of a single dose of IBIO-600

    AUC

    Time frame: Baseline to infinity (AUC0-inf)

  5. Pharmacokinetics of a single dose if IBIO-600

    t½: half-life

    Time frame: Baseline up to Week 36

  6. Pharmacokinetics of a single dose of IBIO-600

    Apparent total body clearance (CL/F)

    Time frame: Baseline through Week 36

  7. Pharmacokinetics of a single dose of IBIO-600

    Apparent volume of distribution (Vz/F)

    Time frame: Baseline up to Week 36

  8. Pharmacodynamics (PD) of a single dose of IBIO-600

    Change in circulating concentrations of total GDF8

    Time frame: Baseline through Week 36

  9. Pharmacodynamics of a single dose of IBIO-600

    Change in circulating concentrations of total GDF11

    Time frame: Baseline up to Week 36

  10. Pharmacodynamics of a single dose of IBIO-600

    Change in lipid panel tests

    Time frame: Baseline up to Week 36

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for May 2027, 12 months after the start.

Of 338 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 12 months is above that.

Counting every sponsor, half of 443 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2026
First posted
Mar 23, 2026
StartActual
May 24, 2026
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
May 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07487376
Lead sponsor
iBio, Inc.
Responsible party
Sponsor
First posted
Mar 23, 2026
Start date
May 24, 2026
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
May 29, 2026

Study contacts

Cory Schwartz, PhD
Contact
IBIO-600-CT001@ibioinc.com
979-446-0027
Cory Schwartz, PhD
study director · iBio, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion